Champix Safety Brought into Question

More than 800 reports of side effects, including more than 500 reports of psychiatric problems, linked to the smoking-cessation drug Champix have been reported to Health Canada resulting in two warnings being issued by the governmental agency recently. Champix has been on the market in Canada since April 2007. A safety warning has also been issued in the United States. Although evidence is growing that the medication is linked to aggression, depression and suicidal tendencies Health Canada states that the link is unproven and has issued a public advisory only. Meanwhile attorneys in the United States are gearing up to target Chantix (as Champix is known there) for the next round of mass tort litigation involving unsafe pharmaceutical drugs.

This entry was posted in adverse drug reaction and tagged , , . Bookmark the permalink. Comments are closed, but you can leave a trackback: Trackback URL.